Disease: Metastatic melanoma ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE <b>Materials & methods:</b> Physicians-identified BRAF mutant MM patients initiating 1L TT or IO therapies and extracted treatment, disease and clinical outcomes including disease response which were compared between TT and IO and individual regimens. 30799646 2019
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE 182 patients diagnosed with stage IV melanoma from July 2006 to December 2013 and treated with BRAF- and/or MEK-targeted therapy or ICI were prospectively studied. 28601879 2017
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE 21 patients with BRAF mutated metastatic melanoma were enrolled in the protocol with BRAF inhibitors for compassionate use at the University of Modena. 23463675 2013
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF mutations in metastatic melanoma: a possible association with clinical outcome. 12960123 2003
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF mutation was present in 15 of 23 (61%) patients with primary melanoma and in 7 of 12 (58%) patients with metastatic melanoma. 16096377 2005
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE B-RAF inhibitors (BRAFi) have been shown to improve rates of overall and progression-free survival in patients with stage IV metastatic melanoma positive for the BRAF V600E mutation. 22726224 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF(V600) inhibitors have offered a new gateway for better treatment of metastatic melanoma. 22912864 2012
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF p.V600 mutation detection recently became necessary to treat metastatic melanoma patients with vemurafenib. 23159108 2013
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF inhibitor activity in V600R metastatic melanoma. 23237741 2013
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 AlteredExpression disease BEFREE BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. 23307859 2013
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. 23403819 2013
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF mutant protein was recently recognized as therapeutic target in metastatic melanoma. 23555633 2013
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. 24463458 2014
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. 24586605 2014
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF was identified as an oncogene in skin melanoma in 2002, and since 2011 has been a therapeutic target in the treatment of metastatic melanoma. 24602025 2014
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE B-Raf(V600E) inhibitors are an important anticancer drug class for metastatic melanoma therapy. 24901049 2014
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF and NRAS mutation status does not influence survival in metastatic melanoma. 24918823 2014
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF inhibitors vemurafenib and dabrafenib achieved improved overall survival over chemotherapy and have been approved for the treatment of BRAF-mutated metastatic melanoma. 25344914 2014
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF mutation and CDKN2A loss occurred early and TERT promoter mutation later in a case of lethal metastatic melanoma. 25407517 2015
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF-, MEK- and KIT-inhibitors led to improvement in overall survival of patients harbouring mutated metastatic melanoma. 25623140 2015
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF kinase inhibitors have dramatically affected treatment of BRAF(V600E) (/) (K)-driven metastatic melanoma. 25948295 2015
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry. 26630683 2016
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 GeneticVariation disease BEFREE BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting. 27151331 2016
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF inhibitor monotherapy has limited efficacy, in contrast to metastatic melanoma. 27341594 2017
CUI: C0278883
Disease: Metastatic melanoma
Metastatic melanoma 		0.100 Biomarker disease BEFREE BRAF mutational status is crucial for the management of metastatic melanoma. 27790766 2017